Ironwood Pharmaceuticals (IRWD) Q4 2024 Earnings Call March 31, 2025 12:02 PM ET Company Participants Greg Martini - CFOThomas McCourt - CEOMichael Shetzline - SVP, Chief Medical Officer and Head of Research & DevelopmentJason Butler - Managing Director & Biotechnology Equity ResearchKatherine Wang - Equity AssociateMatthew Cowper - Vice President - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareDavid Amsellem - Sr. Research Analyst Operator My ...

Financial Data and Key Metrics Changes - Curis reported a net loss of $9.6 million or $1.25 per share for Q4 2024, compared to a net loss of $117 million or $2.03 per share for the same period in 2023 [19] - For the full year 2024, the net loss was $43.4 million or $6.88 per share, compared to a net loss of $47.4 million or $8.96 per share in 2023 [19] - Research and development expenses were $9 million for Q4 2024, down from $10 million in Q4 2023, primarily due to lower clinical and research costs [19][20] - General and administrative expenses decreased to $3.4 million in Q4 2024 from $4.9 million in Q4 2023, attributed to lower legal and consulting costs [20][21] Business Line Data and Key Metrics Changes - In the NHL segment, the TakeAim Lymphoma study is evaluating emavusertib in combination with ibrutinib, with positive feedback from EMA and FDA regarding potential accelerated approval pathways [6][12] - The study has 30 clinical sites open for enrollment, aiming to complete enrollment in the next 12 to 18 months [8][12] - In the AML segment, emavusertib showed a 38% composite CR rate in a study involving patients with FLT3 mutations, indicating strong efficacy compared to existing treatments [14][15] Market Data and Key Metrics Changes - The company has received Orphan Drug Designation for emavusertib in primary CNS lymphoma in both the U.S. and Europe, enhancing its market position [12] - The discussions with regulatory agencies indicate a favorable environment for potential approvals, as there are currently no approved treatments for primary CNS lymphoma [43] Company Strategy and Development Direction - The company is focused on accelerating the development timeline for emavusertib, with plans to enroll additional patients to support filings for accelerated approval [8][12] - There is an ongoing strategy to explore partnerships with major players in the NHL and AML spaces, indicating a proactive approach to enhance its market presence [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical data and the clarity received from regulatory agencies, which supports the company's development plans [12][42] - The company anticipates maintaining a cash runway into Q4 2025, with a quarterly burn rate of approximately $10 million [26][22] Other Important Information - The company completed a registered direct offering and private placement with net proceeds of approximately $10.8 million, extending its financial runway [21] - The company is currently conducting a Phase 1 study of emavusertib in combination with venetoclax and azacitidine for frontline AML, with ongoing enrollment [16][52] Q&A Session Summary Question: Can you talk about cash runway and expenses going forward? - Management confirmed a quarterly burn rate of about $10 million, extending the cash runway to Q4 2025 due to recent offerings [26] Question: Any potential inbound interest from partners? - Management indicated ongoing discussions with potential partners, given the promising data in NHL and AML [28] Question: How many patients have been dosed with emavusertib? - A total of 13 patients have been dosed at 100 mg BID in the study [35] Question: What does the EMA expect in terms of response rates? - Management noted that both agencies are supportive and expect compelling data, with a response rate above 25% being favorable [43] Question: How should we think about TakeAim Leukemia? - Management emphasized caution regarding data expectations in leukemia but highlighted ongoing studies and interest in monotherapy extensions [50][55]

Financial Data and Key Metrics Changes - The company's net revenue for 2024 increased approximately 20% to about $11.7 million compared to $9.8 million in 2023 [6][40] - Total net revenue for Q4 2024 was approximately $3.5 million, representing a 53% increase from Q4 2023's $2.3 million and a 13% increase from Q3 2024's $3.1 million [6][40] - Loss from operations decreased from $34.3 million in 2023 to $30.8 million in 2024 [41] - Net loss attributable to common shareholders decreased from $41.3 million in 2023 to $38.5 million in 2024 [42] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased approximately 3.9% in 2024 compared to 2023 [41] - Mytesi prescription volume increased by about 9.4% in Q4 2024 over Q4 2023 [41] Market Data and Key Metrics Changes - The company is focusing on rare diseases and supportive care for cancer patients, particularly targeting intestinal failure and cancer therapy-related diarrhea [10][32] Company Strategy and Development Direction - The company is pursuing multiple near-term catalysts expected in Q2 2025, which are viewed as significant and value-enhancing [7][43] - The focus is on developing crofelemer for rare diseases and expanding Mytesi's indications to include cancer therapy-related diarrhea [26][36] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of upcoming catalysts and the potential for significant collaborations and licensing deals [13][43] - The company is optimistic about the potential for crofelemer to receive fast-track designations from regulatory agencies due to the lack of approved treatments for certain conditions [25][27] Other Important Information - The company is conducting ongoing proof-of-concept trials for crofelemer in rare diseases, with initial results expected in Q2 2025 [21][22] - The company has developed a novel formulation of crofelemer specifically for patients with intestinal failure, which differs from the commercialized version [30][29] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session [46]

Loar Holdings Inc. (LOAR) Q4 2024 Earnings Conference Call March 31, 2025 08:30 AM ET Company Participants Operator - Conference Call OperatorIan McKillop - Director of Investor RelationsDirksen Charles - Chief Executive Officer and Executive Co-ChairmanBrett Milgram - Executive Co-ChairmanGlenn D'Alessandro - Treasurer and Chief Financial OfficerUnknown Speaker - Unknown Conference Call Participants Sheila Kayalu - Analyst (via Jeff Reiss)Christine Lewak - Analyst at Morgan StanleyJason Gurski - Analyst at ...

Financial Data and Key Metrics Changes - The company reported revenues of $40 million for year '24, a decrease from the record $44 million in year '23, reflecting a return to normalized purchasing after post-COVID restocking [15] - For year '25, the company projects revenues of $44 million and net income of $2.5 million, indicating a 10% year-over-year increase [16][23] - The backlog increased by 35% to $27 million at the end of year '24, driven by exposure to the booming defense sector [16] Business Line Data and Key Metrics Changes - The supply chain division has doubled its engineering team and tripled the number of manufacturers represented, enhancing market position and growth trajectory [7] - The RFID division is expanding its salesforce to capture the rebound in the Israeli civil market and will add off-the-shelf packing machines for logistics centers [18] - The robotic division is preparing for its first installation of a robotic production line in Europe in the first half of year '25 [19] Market Data and Key Metrics Changes - The Israeli defense budget rose by 73% year-over-year, while Europe's defense budget increased by 16% year-over-year, positively impacting key clients [17] - The company has achieved $4 million in overseas sales in year '24 from its supply chain division, indicating successful international expansion [19] Company Strategy and Development Direction - The growth strategy focuses on strengthening relationships with defense clients and expanding internationally [17] - The company aims to deepen its offerings to defense clients, including the recent addition of cable in line [18] - The company is leveraging its Israeli defense client base to align with their global subcontractors for international growth [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for year '25, citing a growing backlog and favorable trends in the defense sector [16][23] - The company is in excellent financial shape with $21 million in equity and zero bank debt, providing flexibility for strategic growth [23][24] - Management highlighted the significant discount at which the company is trading compared to broader market benchmarks, indicating a compelling investment opportunity [20][21] Other Important Information - The company has partnered with a US-based investor relations firm to enhance its presence in the US capital market, resulting in increased trading volume from 4,000 shares to 58,000 shares [21][22] - The company recorded an impairment charge of $1.2 million related to goodwill, impacting net income for year '24 [32] Q&A Session Summary Question: Guidance on the new robotics line in Europe and its impact from the war in Ukraine - Management clarified that they do not have direct sales in Europe but align with major Israeli clients who export and require local production [28][29] Question: Clarification on tax loss carry forward - Management confirmed approximately $30 million in carry forward tax losses, which could provide up to $6 million in future tax savings, with only $1 million recognized as an asset [31] Question: Impact of new head of procurement on defense contracts - Management expressed confidence that the new hire will help capitalize on opportunities in the defense market and indicated updates will be provided if significant developments occur [35]

Lazydays Holdings, Inc. (LAZY) Q4 2024 Earnings Conference Call March 31, 2025 08:30 AM ET Company Participants Operator - Conference Call OperatorJeff Needles - Chief Financial OfficerRon Fleming - CEOAmber Dillard - Chief Operating Officer Operator Greetings and welcome to the Lazy Day RV Holdings 2024 Earnings Release Conference Call. At this time, all participants are on a listen-only mode. If anyone requires operator assistance during the conference, please press star zero on your telephone keypad. As ...

Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Conference Call March 31, 2025 08:30 AM ET Company Participants Operator - Conference OperatorMichael Wood - Conference Call HostChaim Liebowitz - President and CEOAla Patelist - Interim Chief Financial OfficerUnidentified - Unspecified Company RepresentativeDr. Haro Hartonian - EVP and Chief Operating OfficerDr. Bob Dagger - EVP and Chief Medical Officer Conference Call Participants Jason McCarthy - Analyst, Maxim GroupDavid Bouts - Analyst, Zacks S ...

Financial Data and Key Indicators Changes - In 2024, the total net profit increased by 4.8% to RMB222.7 billion, while operating income rose by 2.3% to RMB711.4 billion [4] - Interest income reached RMB580.7 billion, reflecting a growth of 1.6% [4] - Newly added loans amounted to RMB2.29 trillion, marking a significant increase of 10.13% [4] - The non-performing loan (NPL) ratio improved to 1.3%, down by 3 basis points from the previous year [5] - The capital adequacy ratio (CAR) increased by 1.05%, with the Common Equity Tier 1 (CET1) CAR at 11.42% [6] Business Line Data and Key Indicators Changes - The growth of corporate and individual loans outpaced peers, with individual loans showing a discrepancy of 0.42% [5] - The loan balance for county-level growth exceeded RMB1 trillion, accounting for over 40% of the domestic loan balance [9] - Agricultural loans surpassed RMB1 trillion, with a growth rate exceeding 15% [10] - The balance of inclusive finance loans increased by over 30% for six consecutive years, reaching RMB4.66 trillion [15] Market Data and Key Indicators Changes - The stock price of A shares and H shares increased by 55% and 58% respectively, ranking first among comparable peers [7] - The county-level loan balance reached RMB9.85 trillion, with a growth rate of 12.3% [68] - The personal loan balance reached RMB9 trillion, leading among peers [98] Company Strategy and Development Direction - The company focuses on enhancing financial services in agriculture and rural areas, aligning with government strategies [8] - Emphasis on digital transformation and fintech innovation to improve service delivery and customer experience [12][25] - Plans to strengthen risk management and maintain stability in asset quality while supporting the real economy [29][83] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining profitability growth in 2025, driven by supportive macroeconomic policies and consumption boosting measures [27][40] - The outlook for asset quality remains stable, with expectations of maintaining a good level of NPL ratios [81] - The company aims to enhance customer satisfaction and improve reform and innovation in its operations [30] Other Important Information - The company plans to hire 32,000 employees in 2024, focusing on risk control and development [22] - The provision coverage ratio stands at 299%, indicating strong risk resilience [6] - The company has implemented measures to support small and micro borrowers, enhancing its inclusive finance initiatives [14] Q&A Session Summary Question: What is the reason behind the operating income and profit growth in 2024, and what is the expectation for sustainability? - Management attributed the growth to improved credit structure, pricing optimization, and effective risk cost control, with confidence in maintaining profitability growth in 2025 [35][40] Question: What is the outlook for deposit growth in 2024? - Management expects balanced deposit growth, supported by favorable monetary policies and customer base expansion [49][54] Question: What are the reasons for the increase in credit growth in 2024? - The increase is attributed to strategic focus on key areas, with corporate loans growing by 10.6% and individual loans by 9.4% [68][70] Question: What measures will be taken to manage asset quality risks? - Management emphasized stringent risk management practices, focusing on customer eligibility and proactive risk mitigation strategies [78][83] Question: What is the strategy for retail business development? - The company aims to enhance customer management, digital transformation, and expand personal loan offerings to meet growing consumer demand [90][98]

Financial Data and Key Metrics Changes - For the full year of 2024, revenue increased to $56 million from $44.5 million in 2023, while cost of goods sold rose to $52 million from $45.8 million [40] - GAAP gross margin for 2024 was a profit of $4 million or 7.1%, compared to a loss of $1.3 million or negative 2.9% in 2023 [40] - Non-GAAP gross margin for 2024 was a profit of $10 million or 18%, compared to a loss of $2.3 million or negative 5.2% in 2023 [40] - In Q4, revenue was $11.5 million, down from $15.8 million in Q3, with cost of goods sold increasing to $15.2 million from $12.9 million in Q3 [41][42] - Q4 GAAP gross margin was a loss of $3.7 million or negative 32.4%, significantly impacted by inventory reserves and write-offs [42] Business Line Data and Key Metrics Changes - In Q4, the company delivered 51 units, reflecting a 27.3% decline in top-line revenue compared to Q3 due to seasonal delays in the parcel delivery segment [11][16] - The step-van business is expected to shift positively towards strip chassis deliveries, which can reduce inventory turnover by two to three months [17] - The powertrain business made significant progress, with the first powertrain product delivered for a Bluebird electric school bus [18] Market Data and Key Metrics Changes - The company has secured major commercial orders, including nearly 200 strip chassis for UPS and 20 hub units for Caltrans, indicating strong demand across various sectors [14] - The hub product has seen increased demand, with customers including Waymo and Duke Energy, and production rates reached approximately two hub units per week [20][32] Company Strategy and Development Direction - The company aims to continue growing revenue, improving liquidity, and expanding margins while adapting to regulatory changes and infrastructure challenges in the EV market [50] - There is a focus on American manufacturing, with significant investments in the Tennessee facility to support operations [38] - The company is exploring alternative sourcing strategies to mitigate potential tariff impacts and enhance its supply chain [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand pipeline despite challenges from seasonal delays and potential tariff impacts [11][10] - The outlook for 2025 anticipates revenue between $50.2 million and $65.8 million, with unit deliveries expected to range from 320 to 420 units [48] - Management remains focused on achieving positive gross margins and improving working capital efficiency [72] Other Important Information - The company closed a significant transaction that added over $40 million in liquidity to its balance sheet [15] - Inventory decreased to $36.6 million from $42.6 million last quarter, reflecting improved inventory management practices [47] Q&A Session Summary Question: Gross margin performance despite lower volume - Management attributed strong margins to a shifting product mix, particularly with specialty products like the XS Hub [56] Question: Hub business outlook and production capacity - Management indicated plans to increase hub capabilities and production capacity based on customer demand [60][62] Question: FMVSS certification for powertrain business - The powertrain business requires deep partnerships for engineering validation and testing, with production units expected to be shipped to end-user customers [68] Question: Balance sheet and working capital improvements - Management emphasized the goal of improving working capital usage and reducing inventory levels through strategic partnerships and delivery shifts [72][75] Question: Margin growth expectations for 2025 - Management anticipates continued positive gross margins and year-over-year growth on an adjusted basis [80] Question: Environmental credit revenue in Q4 - No environmental credit revenue was reported in Q4, contrasting with the previous quarter [89] Question: Unit mix and guidance for 2025 - An increased mix of hubs, which have higher average selling prices, was noted, with expectations for continued demand in 2025 [92] Question: CapEx expectations for 2025 - Management does not anticipate significant CapEx beyond maintenance and minor investments, given the current capacity of the Tennessee plant [94]

Financial Data and Key Metrics Changes - For the three months ended December 31, 2024, the company reported a net loss of $24.7 million, primarily driven by an impairment of California assets [25] - The company reduced the carrying value of California properties to zero, resulting in a $19.7 million impairment expense [26] - General and administrative expenses decreased to approximately $2.7 million from $6.8 million, demonstrating a significant reduction in corporate overhead [27] - The company closed 2024 with a working capital balance of approximately $27.5 million and cash of approximately $31.2 million [28] Business Line Data and Key Metrics Changes - The company has shifted focus towards its highest grade and highest potential return projects in Southwest Arkansas and East Texas, ceasing material future capital expenditures towards California properties [26] - The demonstration plant expenses decreased from approximately $2 million to $0.8 million, reflecting improved operational efficiency [27] Market Data and Key Metrics Changes - The company has commenced a rigorous project finance and customer offtake selection process for the first phase of the Southwest Arkansas project, indicating a proactive approach to securing funding and partnerships [11] - The East Texas assets have shown the highest lithium concentrations per liter of brine in the company's portfolio, with a significant area of interest identified [13] Company Strategy and Development Direction - The company aims to prioritize resources and activities that will produce the highest returns for shareholders, focusing on the most economic resources in Southwest Arkansas and East Texas [14] - A strategic partnership with Equinor has been established to accelerate progress and enhance project development [6][7] - The company plans to use the demonstration plant in Union County as a testbed for technology development and process improvement [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the support received from local, state, and federal leadership regarding the Southwest Arkansas project [11] - The company anticipates a positive outcome regarding the Arkansas royalty rate by the end of the second quarter of 2025 [42] - Despite uncertainties in pricing and demand, the company remains committed to advancing asset development with a focus on operational efficiency [34] Other Important Information - The company has finalized a $225 million DOE grant, which is seen as a significant vote of confidence for the Southwest Arkansas project [10] - The company has identified an area of interest spanning over 185,000 acres in East Texas, with plans to publish a maiden inferred resource report in the third quarter of 2025 [12][13] Q&A Session Summary Question: Potential benefits from the US administration's executive order on increasing American mineral production - Management views the executive order positively, believing it may facilitate regulatory approvals and open avenues for additional funding [37] Question: Expected timeline for the final outcome on the Arkansas royalty structure - Management is confident of a positive outcome by the end of the second quarter of 2025 [42] Question: Status of the Lanxess project - Management indicated that while the Lanxess project remains important, the focus is currently on developing higher-grade resources in Southwest Arkansas and East Texas [44] Question: Scope of potential offtake agreements - The company initially approached around 40 potential counterparties for offtake agreements, narrowing down to advanced discussions with several key players [51] Question: Impact of learnings from Southwest Arkansas on East Texas projects - Management aims to leverage institutional knowledge and relationships developed in Southwest Arkansas to streamline project development in East Texas [58]